Coherus Oncology, Inc. Common Stock (CHRS)
Coherus BioSciences, Inc. is a biotechnology company focused on developing and commercializing biosimilar and biologic therapies. The company aims to provide affordable alternatives to existing biologic treatments in areas such as oncology, immunology, and ophthalmology. Coherus focuses on advanced biologic products and has a portfolio that includes biosimilars for popular reference drugs.
Company News
Coherus BioSciences announced it will repurchase $170 million of its convertible notes and divest its UDENYCA franchise to Intas Pharmaceuticals. The company plans to repurchase the remaining $60 million of convertible notes after the divestiture closes.
Pfizer's impressive financial results and promising clinical trials make it an undervalued asset in the pharmaceutical industry.
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The company fell well short of expectations for its fourth quarter.
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday. Here are some other stocks moving in today's mid-day session. Gainer...